LONGETRICS
100-Year Human Aging Study
Purpose
The purpose of the 100-Year Human Aging Study is to build a clinical testing platform that accurately measures aging, rate of aging, predicts longevity, predicts future adverse health events, death, and can be utilized to test therapeutics and interventions intended to slow or reverse aging. The principal aim of the 100-Year Human Aging Study is to improve the health, longevity, and performance of participants as well as future generations of humans.
Principle Investigator
Methods
The 100-Year Human Aging Study is a pragmatic-prospective observational clinical trial.
Institutional Review Board (IRB)
Brittany Bonser
Karlee Brandenburg
Sean Bonser
Longetrics Ethics Board (IRB): Approves and Monitors the 1000 Year Human Aging Study for the safety and benefit of all research participants.
Background
The average modern human lifespan is about 78 years in developed nations. The oldest person in recorded history lived 122 years. But, many people in the longevity space believe that emerging new technologies will lead to massive increases in both the quality and length of human life.
Right now, advances in biotechnology, artificial intelligence, and geoscience are leading to breakthroughs in our ability to understand and even manipulate aging in model organisms. But translating these breakthroughs into clinical practice for humans will be very challenging and will take a very long time to validate scientifically.
When studying human longevity, mortality (or death) is the ultimate endpoint of interest. All other potential markers of longevity are surrogate endpoints that must be studied against the actual endpoint we care about, death. A surrogate endpoint is a measurable factor used as a substitute for the endpoint of interest. Surrogate endpoints often make research easier and faster. But the relationship between surrogates and the actual endpoints of interest are often different than researchers originally hypothesized and prone to error.
In research, all surrogate endpoints must be validated against the actual endpoint of interest. Any treatments used to extend the length of life must show an all-cause mortality (death) benefit. Because humans live 78 years, studies lasting 5, 10, or even 20 years will likely be insufficient. A much longer trial is needed if we are to monitor death. As such, measuring aging accurately will take 20 to 50 years to fully validate. Treatments intended to slow or reverse aging will likely take even longer.
For this reason, Longetrics is launching the 100-Year Human Aging Study. The work we are doing will likely take a century to fully validate in clinical medical practice. As such, we have broadened our time horizon and are launching a multi-generational research project.
Increasing age is the greatest risk factor for chronic disease, debility, and death. As such, the ability to accurately measure and subsequently target aging therapeutically is of great importance to humanity. We believe it will also be required for humans to become a multi-planetary species.
Big problems like aging take time to solve. Advances in clinical medicine take time to ensure safety and efficacy. We are in this for the long hall. Join us in solving this 100-year problem.
Ready to Participate?
Join the waitlist for Your Longevity Report Card, Longetrics revolutionary health screening protocol. The knowledge gained will not only benefit you, but all of humanity.